



This is a repository copy of *Revealing a novel nociceptive network that links the subthalamic nucleus to pain processing*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/135076/>

Version: Accepted Version

Article:

Pautrat, A., Rolland, M., Barthelemy, M. et al. (6 more authors) (2018) Revealing a novel nociceptive network that links the subthalamic nucleus to pain processing. eLife. ISSN 2050-084X

<https://doi.org/10.7554/eLife.36607>

© 2018 Pautrat et al. This is an author produced version of a paper subsequently published in eLife. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 Revealing a novel nociceptive network that links the subthalamic nucleus to pain processing

2

3 Arnaud Pautrat¹², Marta Rolland¹², Margaux Barthelemy¹², Christelle Baunez⁵, Valérie
4 Sinniger²⁴, Brigitte Piallat¹², Marc Savasta¹², Paul G. Overton³, Olivier David¹² and Véronique
5 Coizet^{*12}

6

7 ¹Inserm, U1216, F-38000 Grenoble, France

8 ²Univ. Grenoble Alpes, GIN, F-38000 Grenoble, France

9 ³Department of Psychology, University of Sheffield, Sheffield, S10 2TP, UK

10 ⁴Service d'Hépatogastroentérologie, CHU Grenoble, F-38043, France

11 ⁵Institut de Neurosciences de la Timone, UMR7289 CNRS & Aix-Marseille Université, F-13000
12 Marseille, France

13

14 *Corresponding author and Lead contact: Veronique Coizet

15 Grenoble Institute of Neuroscience

16 Bâtiment E.J. Safran - Chemin Fortuné Ferrini - 38700 La Tronche FRANCE

17 Tel: +33 4 56 52 05 99 (secr) / Fax: +33 4 56 52 05 98

18 e-mail: veronique.coizet@univ-grenoble-alpes.fr

19

20

21

22

23

24

25

26

27

28

29

30 **SUMMARY**

31 Pain is a prevalent symptom of Parkinson’s disease, and is effectively treated by deep brain
32 stimulation of the subthalamic nucleus (STN). However, the link between pain and the STN
33 remains unclear. In the present work, we report that STN neurons exhibit complex tonic and
34 phasic responses to noxious stimuli using *in vivo* electrophysiology in rats. We also show that
35 nociception is altered following lesions of the STN, and characterize the role of the superior
36 colliculus and the parabrachial nucleus in the transmission of nociceptive information to the
37 STN, physiologically from both structures and anatomically in the case of the parabrachial
38 nucleus. We show that STN nociceptive responses are abnormal in a rat model of PD,
39 suggesting their dependence on the integrity of the nigrostriatal dopaminergic system. The
40 STN-linked nociceptive network we reveal is likely to be of considerable clinical importance
41 in neurological diseases involving a dysfunction of the basal ganglia.

42

43 **KEYWORDS**

44 Subthalamic nucleus, nociception, nociceptive network, subcortical hyperdirect pathway,
45 parabrachial nucleus, superior colliculus

46

47

48

49

50

51

52

53

54 **INTRODUCTION**

55 Pain is highly prevalent in Parkinson's disease (PD) and includes primary symptoms assumed
56 to originate from a dysfunction of the central nervous system. Patients describe bizarre and
57 unexplained painful sensations such as painful burning, stabbing, aching, itching or tingling
58 sensations, predominating on the more affected side (Schestatsky et al., 2007). These
59 symptoms are not directly related to the pain caused by the motor symptoms (Ha and
60 Jankovic, 2011). Sensitivity to noxious stimulation is also increased in patients with PD, with
61 or without pain symptoms (Berardelli et al., 2012; Brefel-Courbon et al., 2013; Tinazzi et al.,
62 2008), and their nociceptive threshold is altered (Chudler and Dong, 1995; Conte et al., 2013;
63 Djaldetti et al., 2004). Although it is well known that PD affects the basal ganglia, there is to
64 date no clear description of a link between the basal ganglia and the cerebral network
65 involved in pain. Interestingly, deep brain stimulation of the subthalamic nucleus (STN-DBS)
66 in PD, a valuable and effective therapeutic technique for motor symptoms (Krack et al.,
67 2003; Limousin et al., 1998), has also been shown to reduce pain (Cury et al., 2014; Hanagasi
68 et al., 2010; Kim et al., 2008; Klingelhoefer et al., 2014). In contrast, the effects of dopamine
69 replacement therapy on the pain symptoms in PD are controversial, with some
70 investigations reporting an improvement, no effect or an aggravation of pain symptoms or
71 nociceptive thresholds (Conte et al., 2013, Dellapina et al., 2011). These variable results of
72 dopamine replacement therapy indicate a role for other systems in the pain symptoms
73 observed in PD. Importantly in the present context, it has been demonstrated that pain relief
74 following STN DBS is superior to that following dopaminergic treatment, further positioning
75 STN as a crucial structure in pain symptoms in PD and their relief (Sürücü et al., 2013).

76 The mechanism by which STN-DBS improves pain in PD patients remains unclear, which
77 raises a fundamental question about the link between the subthalamic nucleus (STN) and

78 pain. Preliminary evidence suggests that noxious stimulation can modulate background
79 activity in the STN, at least in the parkinsonian brain (Belasen et al., 2016; Heise et al., 2008).
80 As a consequence, the STN could be linked to a nociceptive network involved in the
81 perception of noxious stimuli, although this has yet to be fully explored. Despite the classical
82 description of a sensory territory in the STN (Alexander et al. 1986) and the functional
83 impact that STN sensory responses could have on the basal ganglia (Baunez et al., 2011),
84 there is a paucity of information in the literature regarding the type of sensory stimuli
85 activating this structure and the afferent sensory source(s) (Coizet et al., 2009; Hammond et
86 al., 1978; Matsumura et al., 1992). Two major subcortical central targets for ascending
87 nociceptive information from the spinal cord are potential relays for nociceptive information
88 to the STN: the superior colliculus (SC) and the parabrachial nucleus (PBN) (Hylden et al.,
89 1989; Craig, 1995; Klop et al., 2005; McHaffie et al., 1989).

90 We have shown that the SC, a highly conserved but evolutionarily ancient subcortical multi-
91 sensory structure, directly projects to the STN and is the primary, if not exclusive source of
92 visual input to the STN (Coizet et al., 2009; Tokuno et al., 1994). This projection shows that
93 subcortical hyper-direct pathways exist between brainstem sensorimotor structures and the
94 STN which predate, from an evolutionary perspective, those from the cortex thus reinforcing
95 the position of the STN as a critical input structure processing short latency visual signals in
96 the basal ganglia (Baunez et al., 2011). The substantia nigra pars compacta (SNc) is also on
97 the input side of the basal ganglia and we have shown that SNc receives nociceptive-related
98 afferents from the PBN (Coizet et al., 2010), raising the possibility that the STN may also
99 receive such inputs.

100 It is interesting to note that the STN is well known to heavily project to basal ganglia output
101 structures such as the substantia nigra pars reticulata (SNr) (Alexander et al., 1986; Gurney

102 et al., 2001), which in turn projects to the SC and PBN (Schneider, 1986; Deniau and
103 Chevalier, 1992), linking the STN, SNr and SC/PBN anatomically. With the STN in a position to
104 modulate a nociceptive network involving the SC/PBN, the elevated activity in the STN in
105 parkinsonism (Bergman et al., 1994; Albin et al., 1995) could underlie some unexplained pain
106 symptoms in this disease, with STN-DBS acting (at least in part) locally to achieve its
107 analgesic effects. Nociceptive processing in the STN would also be consistent with the
108 nucleus's role as part of brain's interrupt circuitry (Jahanshahi et al., 2015), terminating
109 behaviors that achieve negative outcomes, of which pain is a clear example.

110

111 Therefore, the main objective of the present work was to characterize the link between STN
112 and nociception, answering the following questions:

113 - Does the STN process nociceptive information? We explored the possibility that noxious
114 stimulation could induce nociceptive responses in the rat STN with *in vivo* electrophysiology.

115 - Is the STN linked to a nociceptive network? We tested the potential role of the SC and PBN
116 in the transmission of nociceptive information to the STN, both physiologically and in the
117 case of the PBN, anatomically.

118 - Can manipulation of the integrity of the STN change nociceptive responses measured
119 behaviorally? We tested STN lesioned and sham operated rats using a hot plate test.

120 - Finally, to examine the hypothesis that STN dysfunction could underlie some pain
121 symptoms observed in PD, we evaluated if STN nociceptive responses were abnormal in a rat
122 model of PD.

123 We present convergent evidence that the STN is functionally linked to a nociceptive network
124 and that STN nociceptive responses are affected in parkinsonism. The objectives above are
125 summarized in figure 1.

126

127 RESULTS

128 *Nociceptive responses in STN*

129 **STN neurons:** A total of 98 cells were recorded across the STN (Figure 2A). The STN neurons
130 sampled in the present study were characterized by a triphasic action potential in majority of
131 cases (n = 88, mean duration = 2.1 ± 0.06 ms), the remaining cells having a biphasic action
132 potential (n = 10, mean duration 1.58 ± 0.12 ms) (Figure 2B). The STN cells had a mean
133 baseline firing rate of 7.39 Hz (± 0.53 Hz) and exhibited various spontaneous patterns of
134 activity such as an irregular pattern (n = 42, 43 %), a regular pattern (n = 26, 27 %) and a
135 bursting pattern (n = 20, 20 %) (Figure 2C). The remaining cells (n = 10, 10 %) exhibited a
136 mixture of these features. These electrophysiological characteristics are concordant with
137 those reported elsewhere in the literature in anesthetized rats (Hassani et al., 1996; Kreiss et
138 al., 1996; Hamani et al., 2004).

139

140 **Phasic response** (Figure 3A): Following noxious stimulation performed on the contralateral
141 hindpaw (120, 0.5 Hz), 19 STN cells remained unresponsive (19 %) while 79 STN neurons (81
142 %) exhibited a phasic response to the footshock with several patterns of response:

143

144 I. Monophasic excitation (n = 42): The response consisted of a monophasic excitation. This
145 type of response could be subdivided into three categories according to their latencies and
146 durations:

147 1) Monophasic short/long (n = 20, Figure 3Aa): The cells exhibited a short latency, long
148 duration excitation;

149 2) Monophasic short/short (n = 17, Figure 3Ab): The cells exhibited a short latency,
 150 short duration excitation;

151 II. Biphasic +/+ (n = 22, Figure 3Ac): The cells had an initial short-latency, short duration
 152 excitation followed by a longer latency and longer duration excitation;

153 III. Biphasic +/- (n = 10, Figure 3Ad): The response in these cells had two phases, a short
 154 latency, short duration excitation followed by an inhibition.

155 IV. Triphasic +/-/+ (n = 5, Figure 3Ae): The response was characterized by an initial short
 156 latency, short duration excitation, then an inhibition or a marked reduction in firing rate
 157 followed by third late latency and long lasting excitation.

158 The remaining phasic responses could not be classified this way (n = 5).

159 The details of the latencies and durations of each response types can be found in the table 1
 160 below:

| RESPONSE TYPES | | PHASE 1 | | PHASE 2 | | PHASE 3 | |
|----------------|----|--------------------|----------------------|----------------------|----------------------|---------------------|--------------------|
| | | LATENCY | DURATION | LATENCY | DURATION | LATENCY | DURATION |
| I. | 1. | 37,80 ± 3,15 ms | 338.40 ± 49.79 ms | / | / | / | / |
| | 2. | 20.18 ± 3.15 ms | 34.47 ± 3.92 ms | / | / | / | / |
| II. | | 20.00 ± 3.02 ms | 35.00 ± 3.86 ms | 97.00 ± 6.97 ms | 269.00 ± 40.05 ms | / | / |
| III. | | 23.00 ± 4.61 ms | 69.00 ± 19.59 ms | 133.70 ± 32.76 ms | 176.70 ± 3.83 ms | / | / |
| IV. | | 16.4 ± 4.57 ms | 46.4 ± 7.90 ms | 101.2 ± 18.56 ms | 28.2 ± 5.27 ms | 227.6 ± 43.53 ms | 216.8 ± 69.3 ms |

161
 162 A significantly larger number of non-responding cells were located in the caudal portion of
 163 STN ($\chi^2 = 6.94$, $df = 2$, $p < 0.05$, Figure 2A). Of the 24 cells activated by noxious stimulation
 164 which were tested for multi-modal responses, only three exhibited an excitation to non-
 165 noxious somatosensory stimulation (light brush), hence the majority were nociceptive only
 166 cells.

167

168 **Baseline firing rate** (Figure 3B): The introduction of noxious stimulation induced a
169 statistically significant increase in STN baseline firing rate (Wilcoxon test: $W[97] = -1199$; $p =$
170 0.05 ; mean \pm SEM: no noxious stimulation: 7.13 ± 0.51 Hz vs noxious stimulation: $7.78 \pm$
171 0.52 Hz). However, we could clearly observe some cells decreasing their baseline firing rate
172 when the footshock was delivered (figure 3B). We therefore performed an individual
173 analysis on each of the 98 STN cells, whether responding to the noxious stimulation or not,
174 to test if the change of their baseline firing rate after the introduction of the stimulation was
175 statistically robust (Wilcoxon test, $p < 0.05$), and if so, in which direction the change took
176 place. We identified 39 (40 %) and 17 (18 %) cells showing a significant increase (“up” group)
177 and decrease (“down” group) of their baseline firing rate with the stimulation, respectively
178 and no significant change for the remaining 42 cells (42 %, “no change” group). Contingency
179 analysis did not reveal a specific topography of their location within STN, or link to their
180 action potential shape, or to the presence or absence of a phasic response. Once grouped
181 together in terms of direction, the “up” and “down” groups both exhibited a statistically
182 significant change in their baseline firing rate (up: Wilcoxon test: $W[38] = -780$, $p < 0.001$;
183 mean \pm SEM: no noxious stimulation: 6.31 ± 0.83 Hz vs noxious stimulation: 9.09 ± 0.94 Hz;
184 down: Wilcoxon test: $W[16] = 153$, $p < 0.001$; mean \pm SEM: no noxious stimulation: $9.55 \pm$
185 1.43 Hz vs noxious stimulation: 7.08 ± 1.26 Hz), unlike the “no change” group (Wilcoxon test:
186 $W[41] = 245$, $p = 0.1272$; mean \pm SEM: no noxious stimulation: 6.92 ± 0.65 Hz vs noxious
187 stimulation: 6.85 ± 0.67 Hz). Interestingly, the spontaneous firing rate of STN cells from the
188 “down” group had a significantly higher firing rate than the “up” and “no change” groups
189 during the control period (Mann-Whitney test: $U = 225$, $p < 0.05$; mean \pm SEM: “up”: $6.31 \pm$
190 0.83 Hz vs “down”: 9.55 ± 1.43 Hz, $U = 261$, $p = 0.05$; mean \pm SEM: “no change”: 6.919 ± 0.65

191 Hz vs “down”: 9.55 ± 1.43 Hz), while the “up” and “no change” groups did not differ
192 significantly. This suggests the presence of a separate population of STN neurons with a
193 higher firing rate.

194

195 ***STN and nociceptive responses: Is nociceptive information in the STN functionally***
196 ***relevant?***

197 To evaluate the involvement of STN in nociceptive responses, we tested nociceptive
198 responses in STN lesioned and sham operated rats behaviorally using a hot plate test. The
199 lesions were positioned within specific sub regions of the STN, sparing the surrounding
200 structures such as the zona incerta or the hypothalamus located above and medial to the
201 STN, respectively. The bi-lateral STN lesions were localized in the posterior half (n = 6) or
202 anterior/central (n = 6) parts of this structure, covering from 8 to 34 % of the total surface of
203 both bilateral STN (mean \pm SEM: 20 ± 2.4 %) (figure 4).

204 These partial and highly localized STN lesions affected the nociceptive responses of the rats.
205 Analysis showed a significant increase of the latency to produce the first sign of discomfort
206 in the hot plate in the STN lesioned group compared to the sham group (mean \pm SEM:
207 control = 10.81 ± 0.83 seconds; STN lesioned = 14.35 ± 0.9 seconds, $p < 0.05$).

208

209 ***Where does nociceptive information in the STN come from?***

210 **Nociceptive responses in afferent structures: SC and PBN:** Footshocks produced short
211 latency, short duration excitatory responses in the SC and PBN (table 2). PBN nociceptive
212 responses were smaller in magnitude and amplitude than those in SC. Footshocks did not
213 change the spontaneous baseline firing rate in the SC or the PBN (SC: $t[7] = 1.218$; $p = 0.13$;

214 PBN: $W = 8$; number of pairs = 11; $p = 0.38$). The latencies of SC and PBN responses to the
215 stimulation were both significantly shorter than those of the STN (SC-STN: $t[15] = 2.88$; $p <$
216 0.001 ; mean \pm SEM: SC: 9 ± 0.8 ms vs STN: 25.33 ± 5.27 ms; PBN-STN: $t[22] = 3.34$; $p < 0.01$;
217 mean \pm SEM: PBN: 11.55 ± 1.35 ms vs STN: 24.54 ± 3.13 ms). Given that the response to
218 noxious stimulation in SC and PBN occurs before the STN, both structures could be part of
219 the nociceptive afferent network directed at the STN.

220

221 **Effect of SC or PBN inhibition on STN nociceptive responses:** To test the possibility that the
222 SC or PBN transmits nociceptive signals to the STN, we pharmacologically inhibited their
223 neuronal activity with muscimol, a GABA_A agonist, and evaluated the effect of their
224 temporary inactivation on STN nociceptive responses. Simultaneous recordings were made
225 from SC (multi-unit) and STN (single unit) neurons ($n = 9$) or from PBN (multi-unit) and STN
226 (single unit) neurons ($n = 13$) before and after the delivery of noxious footshock.

227

228 *Muscimol in the SC (table 2):* The injection of muscimol adjacent to the SC electrode
229 decreased the tonic activity in this structure ($t[7] = 4.31$; $p < 0.001$) and abolished the phasic
230 responses altogether in three cases. In the remaining cases, the muscimol produced a
231 significant reduction of the magnitude ($t[4] = 5.49$; $p < 0.01$), maximum amplitude ($t[4] =$
232 3.18 ; $p < 0.05$), and a trend towards the duration of the response ($t[4] = 1.74$, $p = 0.08$), but
233 did not affect the latency ($p = 0.19$). The depression of the SC neuronal activity by muscimol
234 abolished STN nociceptive response in one case (1/9), and significantly reduced the duration
235 of STN nociceptive responses in the remaining cases ($t[7] = 3.27$; $p < 0.05$), with a trend
236 towards a decrease in magnitude, the difference being close to reaching the statistical

237 threshold ($t[7] = 2.31$; $p = 0.054$). The remaining parameters of the response and the
238 baseline firing rate of STN cells were not statistically different to the pre-drug period.

239 *Muscimol in the PBN (table 2)*: The injection of muscimol adjacent to the PBN electrode
240 significantly decreased tonic activity of this structure ($t[10] = 2.59$; $p < 0.05$) and abolished
241 altogether the phasic nociceptive responses in the PBN in two cases. In the remaining cases,
242 the injection of muscimol increased the latencies ($t[8] = 3.12$, $p < 0.01$) and produced a
243 significant reduction of the duration of the response ($t[8] = 3.44$, $p < 0.01$), the magnitude
244 ($t[8] = 2.88$; $p < 0.01$); and maximum amplitude ($t[8] = 3.91$; $p < 0.01$). Unlike the SC, this
245 general depression of PBN neuronal activity by muscimol completely abolished nociceptive
246 phasic responses in five STN cells (5/13, Figure 5) and significantly reduced numerous
247 parameters of the remaining STN responses to the stimulation, such as the duration
248 (Wilcoxon test: $W = 31$, number of pairs = 8, $p < 0.05$), magnitude ($t[7] = 4.25$; $p < 0.01$) and
249 maximum amplitude ($t[7] = 3.21$, $p < 0.01$). Neither the latency ($t[7] = 0.04$, $p = 0.48$, ns) nor
250 the baseline firing rate ($t[12] = 0.19$, $p = 0.42$, ns) were significantly affected by the injection
251 of muscimol in PBN.

252

253 These results show that PBN pharmacological blockade with muscimol is more effective at
254 reducing STN phasic nociceptive responses.

255

256 **Effect of SC or PBN lesions on STN nociceptive responses:** Suppression of SC activity by
257 muscimol only had a small influence on STN phasic nociceptive responses unlike PBN
258 inactivation. However, while the technique of micro-injection offers a temporary inactivation
259 with a possibility of recovery, the comparison of its effects on STN nociceptive responses
260 versus those following PBN injections could be affected by the fact that muscimol was less

261 effective at reducing SC phasic responses than those in the PBN, and by the difficulty of
262 evaluating the spread of the injection in the SC and PBN. Therefore, we tested the effect of
263 ipsilateral ibotenic acid lesions of the lateral part of SC or PBN, on STN phasic nociceptive
264 responses.

265

266 *SC lesion:* In all cases (n = 5), the lesion included the lateral SC and extended, in some cases,
267 to the adjacent superficial and/or deep layers of this structure (Figure 6A and B). A total of
268 28 STN cells were recorded in lesioned animals before and after noxious footshocks. Of
269 these cells, 27 (94 %) still responded to the noxious stimulation. Analysis of the proportion of
270 responding and non-responding cells between the control and SC lesioned rats showed a
271 significant difference between both groups ($\chi^2 = 2.98$, $df = 1$, $p < 0.05$), with a larger
272 proportion of responding cells in SC-lesioned rats compared to control animals (94 % vs 81
273 %), and hence a facilitation of the occurrence of the STN nociceptive responses after the
274 removal of the lateral SC.

275

276 Analysis of the nociceptive-induced phasic responses in STN showed a close to significant
277 reduction of the duration (Mann-Whitney, $U = 85$, $p = 0.06$), which is consistent with the
278 reduction of duration observed previously after the injection of muscimol in SC. A plot of the
279 distribution of STN responses according to their latency and duration in control and SC
280 lesioned animals shows that this statistical tendency could be due to the loss of the longer
281 lasting nociceptive responses in SC lesioned animals (Figure 6C, dotted line box). This is
282 supported by the observation of an increased proportion of short latency/short duration
283 response types and a decrease in the proportion of long lasting responses (Figure 6D). The

284 other parameters of the response did not differ significantly and the firing rate was
285 statistically unaffected.

286

287 *PBN lesion:* The injection of ibotenic acid in the PBN induced a near total lesion of this
288 structure in one case, extending over 87 % of the PBN. This lesion also affected a small part
289 of the caudal pedunculopontine nucleus. In the remaining cases, the lesion was only partial
290 and affected between 30 to 60 % of this nucleus (Figure 7A and B).

291 A total of 30 STN cells were recorded in PBN lesioned rats before and after noxious
292 footshocks. Although the lesion did not cover the entire PBN, the proportion of responding
293 cells in the STN was significantly reduced, with 15 cells (50 %) still responding to the noxious
294 stimulation while the other 15 (50 %) did not respond. Analysis of the proportion of
295 responding and non-responding cells between the control and PBN lesion rats showed a
296 significant difference between both groups ($\chi^2 = 11.03$, $df = 1$, $p < 0.001$), with a larger
297 proportion of non-responding cells in PBN lesioned rats compared to control animals (50 %
298 vs 19 %), representing a significant suppression of STN nociceptive responses after the
299 removal of the PBN. Analysis of the nociceptive-induced phasic responses in the responding
300 STN cells showed a significant reduction of response duration (Mann-Whitney, $U = 378$, $p =$
301 0.05), which is consistent with the reduction of duration previously observed after the
302 injection of muscimol in PBN. However, unlike the pharmacological blockade, the magnitude
303 and maximum amplitude of the responses were not affected. As expected, the latency and
304 the baseline firing rates were not statistically different between PBN lesioned and control
305 rats.

306 A plot of the distribution of STN nociceptive responses according to their latency and
307 duration in control and PBN lesioned animals shows that most types of responses described

308 in control rats disappeared. A cluster of responding cells with short latencies and durations
309 remained (Figure 7C and D).

310

311 **Anatomical link between the PBN and the STN:** Our electrophysiological experiments
312 suggest that the PBN acts as a critical source of nociceptive input to the STN and the SC as a
313 critical modulator of those responses. While the connection between the SC and the STN has
314 been previously characterized (Coizet et al. 2009; Tokuno et al., 1994), the functional link
315 between the PBN and the STN was puzzling as a previous neuroanatomical study
316 characterizing afferent connections of the STN reported the absence of labeled terminals
317 and fibers in the STN following the injection of an anterograde tracer in the parabrachial
318 complex (Canteras et al., 1990). However, the characterization of PBN efferent connections
319 has often focused on the amygdala or the hypothalamus, but a close examination of PBN-
320 related fiber pathways, especially to the amygdala, indicates that those fibers are travelling
321 close to (Saper et al., 1980: figure 4F) or even partly within the STN (e.g. Bernard et al., 1989:
322 figure 2J; Sarhan et al., 2005: Figure 9B3). Therefore, to better understand the anatomical
323 basis of our electrophysiological data, we re-evaluated the parabrachio-subthalamic
324 pathway using combination of anterograde and retrograde tract-tracing techniques.

325

326 *Anterograde tract-tracing:* Injections of the anterograde tracers *Phaseolus Vulgaris*
327 leucoagglutinin (PHA-I, n = 4) or biotinylated dextran amine (BDA, n = 4) into the PBN
328 revealed a robust direct projection to the ipsilateral STN and a less substantial projection to
329 the contralateral STN. The ipsilateral ascending fibers leave the PBN in an antero-dorsal
330 direction and pass above and through the dorso-caudal pedunculo-pontine tegmental
331 nucleus (Figure 8). There, they split into three large pathways (Figure 8A), a PBN - SC

332 (intermediate and deep layers), a PBN - thalamic and a PBN – nigral ventral projection. PBN
333 labeled axons traveling to the STN are a rostral extension of the pathway we have previously
334 described (Coizet et al., 2010) from the PBN to the dopaminergic neurons in the ventral
335 midbrain, the parabrachio-nigral pathway. A substantial number of fibers continue further
336 forward to the amygdala and the cortex (Figure 8A). This parabrachio-subthalamic pathway
337 originates in the lateral and medial PBN (lPBN and mPBN respectively). Thus, injections of
338 either PHA-I or BDA centered preferentially on the lPBN or the mPBN were both associated
339 with numerous labeled axons and terminals, which were differentially distributed within sub
340 regions of the STN. PBN fibers and terminals were largely seen in a dorsal sheet that
341 extended across the entire mediolateral axis of the STN (Figure 8B and C). Moving rostrally,
342 they further spread across the dorsoventral area of the STN. Many anterogradely labeled
343 boutons were located in the vicinity of labeled fibers (Figure 8B and C).

344

345 *Retrograde track tracing:* To identify the regional distribution and morphology of the
346 parabrachio-subthalamic projection neurons, we injected small quantities of the retrograde
347 tracers Fluorogold (n = 4) or Cholera toxin subunit B (CTB, n = 2) in the STN. The projection to
348 the STN exhibited little topography. Retrogradely labeled neurons were found in all
349 subnuclei of both the ipsilateral and contralateral PBN, and also within the fibers of the
350 superior cerebellar peduncle (cp) (Figure 9A and B). The density of the labeled cells was
351 however significantly larger on the ipsilateral side, as confirmed by a three factor (Side:
352 ipsilateral/contralateral; Level: AP 8.8/AP 9.3/AP 9.8; Subdivisions: Lateral/medial/cp)
353 repeated-measures ANOVA (Side factor: $F = 9.33$, $df = 1$, $p < 0.05$) and varied within the PBN
354 according to the AP level (interaction between the level and the subdivisions, $F = 4.10$, $df = 4$,
355 $p < 0.05$). The density of the cells increased in the lateral PBN when moving rostrally and the

356 majority of the cells in mPBN were located in the posterior PBN. PBN neurons retrogradely
357 labeled by STN injections are small to medium sized (mean \pm SEM: $229.25 \pm 8.21 \mu\text{m}^2$, range
358 from 102.1 to 681.10; n=184) with a majority of round (59 %) and bipolar (35 %) soma and
359 some multipolar cell bodies (6 %) (Figure 9C).

360

361 ***STN nociceptive responses in a rat model of Parkinson's disease***

362 In a classical rat model of PD induced by an injection of 6-hydroxydopamine (6-OHDA), a
363 neurotoxin targeting dopaminergic neurons (DA), in the SNc, we tested whether STN
364 nociceptive responses were dysfunctional.

365 TH immunohistochemistry was used to assess the extent of the dopamine denervation
366 induced by 6-OHDA in the DA lesioned rats. TH-labeled neurons on the lesioned side were
367 reduced to an average of 6.13 ± 0.71 % (mean \pm SEM) of those on the unlesioned side, with
368 the remaining neurons located in the medial part of the SNc. The reduced number of
369 dopaminergic cells led to an average decrease of 65.22 ± 2.08 % in the dopaminergic
370 innervation of the striatum.

371 A total of 34 and 43 cells were recorded in control and DA lesioned rats, respectively. As
372 expected in a model of PD, STN cells had a significantly higher firing rate in DA lesioned rats
373 compared to controls (mean \pm SEM: control = 8.00 ± 1.04 ms; DA lesioned = 12.96 ± 2.02 ms,
374 $p < 0.05$, figure 3A). STN responses to nociceptive stimulation were abnormal in the DA
375 lesioned group. Analysis revealed that STN cells in PD rats exhibited significantly longer
376 responses (mean \pm SEM: control = 84.39 ± 16.75 ms; DA lesioned = 175.38 ± 39.85 ms, $p <$
377 0.05) with a greater amplitude (mean \pm SEM: control = 27.81 ± 3.58 ms; DA lesioned = 40.88
378 ± 5.91 ms, $p < 0.05$, figure 3C) and magnitude (mean \pm SEM: control = 8.13 ± 1.38 ms; DA
379 lesioned = 13.11 ± 2.47 ms, $p < 0.05$) compared to the sham control animals. The proportion

380 of cells exhibiting the three levels of STN baseline firing rate with the introduction of the
381 stimulation (up, down or no change) was not altered in the PD rat groups ($\chi^2 = 0.32$; $p =$
382 0.85). Therefore, STN phasic nociceptive responses in PD rats were exacerbated, while the
383 tonic modulation of the firing rate was preserved.

384

385 **DISCUSSION**

386 The present study demonstrated for the first time that a large majority of STN neurons
387 exhibit various mono- or multi- phasic responses to noxious stimulation, consistent with the
388 hypothesis that one of the functions of the STN is to interrupt behavior when appropriate
389 (Jahanshahi et al., 2015), in this case to select a more appropriate action to try to relieve the
390 noxious sensation. STN nociceptive responses mainly had a short latency ($\sim 20 - 40$ ms) and
391 could be recorded all over the structure. We have shown that most of responsive cells are
392 nociceptive specific, as only few of them respond to non-noxious somatosensory stimulation
393 as well. In addition, we found that we could differentiate three types of STN neurons, which
394 either showed an increase, a decrease or no change of their baseline firing rate with the
395 introduction of the noxious stimulation. The spontaneous firing rate of STN “down” cells was
396 significantly higher compared to the two other groups, suggesting the possibility of a
397 separate group of cells. Furthermore, we have shown that STN responses to nociceptive
398 stimuli were abnormal in a rat model of PD, suggesting that the nociceptive responses
399 recorded in STN depends on the integrity of the nigrostriatal DA system.

400

401 When determining the afferent source of nociception-related influence on STN activity we
402 have revealed a crucial role for two brainstem structures, the PBN and the SC, by
403 demonstrating the effects of their inactivation on nociceptive responses in the STN and also

404 by highlighting the existence of an anatomical direct pathway from the PBN to the STN. This
405 parabrachio-subthalamic projection represents a second example of a subcortical
406 hyperdirect pathway to the STN from a sensori-motor structure, in addition to the tecto-
407 subthalamic pathway previously described (Coizet et al., 2009; Tokuno et al., 1994). Finally,
408 we have shown that these anatomico-electrophysiological findings translate into a functional
409 role for the STN in mediating nociception, in that nociceptive behavioral responses were
410 affected by lesions of the STN. However, a note of caution required since we used only male
411 rats, and thus care should be taken in extrapolating our results to females.

412

413 Using noxious electrical stimulation of the hindpaw allowed us to precisely record the timing
414 of responses in our structures of interest with controlled parameters of stimulation. It is
415 interesting to note that the majority of STN nociceptive responses had short latencies
416 (76/79) and were monophasic (40/79), which is similar in proportion to the pattern of STN
417 responses following visual stimulation (Coizet et al., 2009) but dissimilar to STN responses
418 following stimulation of the frontal (Magill et al., 2004), sensorimotor (Fujimoto and Kita,
419 1993) or motor cortex (Kolomiets et al., 2001). The latter - in the majority of cases - are
420 multi-phasic, with two excitatory phases (equivalent to the present biphasic +/-) often
421 separated by an inhibition (equivalent to the present triphasic +/-/+). It has been
422 hypothesized previously (Magill et al., 2004; Kitai and Deniau, 1981) that the short latency
423 excitation following cortical stimulation appears to be driven by a hyperdirect pathway to
424 the STN while the later phases of the response arise from polysynaptic interactions, which
425 are slower to manifest. The inhibition following the first excitation has been hypothesized to
426 involve the reciprocally connected STN – globus pallidus (GP) network (Fujimoto and Kitai,
427 1993). STN excitation may activate GP GABAergic neurons, which in return inhibit the STN.

428 Overall, our data suggests that when the rat is subjected to noxious stimulation, the main
429 pathway activated to the STN is a fast hyperdirect pathway, originating in part in the PBN.
430 The fact that we only have a few cells showing an inhibitory second phase (10 biphasic +/-
431 and 5 triphasic, 15/79) indicates that STN nociceptive cells are rarely closely connected to
432 the GP and lack GP-STN feed forward control.

433

434 Functionally antagonistic STN neuronal subpopulations have been found in the STN. Specific
435 GO and STOP cells have been described in PD patients performing a stop signal paradigm,
436 during motor execution or response inhibition, respectively (Benis et al., 2016). Sub-
437 populations of STN cells have also been shown to exclusively code for reward magnitude (4%
438 vs 32 % sucrose, Lardeux et al., 2009), error-related activity (“Oops neurons”, Lardeux et al.,
439 2009), reward value (cocaine or sucrose, Lardeux et al., 2013) and for positive and aversive
440 reinforcers (Breyse et al, 2015). A major finding of our work is that we were able to
441 differentiate a subpopulation of STN neurons with a higher spontaneous firing rate on the
442 basis of the effect of noxious stimuli on general tonic activity. This finding is important since
443 glutamatergic tone from the STN is likely to have a strong impact on the tonic level of
444 activity in the basal ganglia network, especially in the output structures (since we
445 hypothesized that nociceptive-responding STN cells may not be densely connected to GP -
446 see above). The results from previous computational studies (Gurney et al., 2001) suggest
447 that tonic control by the STN may adjust the general level of activity of the inhibitory
448 GABAergic neurons of the BG output structures, known to project to the SC and PBN
449 (Schneider, 1986; Deniau and Chevalier, 1992). This tonic STN control is hypothesized to be
450 used by the BG to optimize selection of the most appropriate action. The identification of
451 separate subpopulations of cells in the STN according to their spontaneous firing rate and

452 orientation of the change of their firing rate following the occurrence of noxious stimulation
453 suggests that the tonic excitatory effects of the STN may not be uniform, although further
454 work is required to elucidate the connectivity of the STN subpopulations. This mechanism is
455 important in the context of PD in which STN activity is pathologically increased (Bergman et
456 al., 1994; Albin et al., 1995), probably disrupting this control. This possibility is further
457 supported by our results showing enhanced phasic nociceptive responses in a PD rat model,
458 with an increase in the latency to make nocifensive responses in the hotplate test following
459 lesions of the STN. As well as interfering with action selection, disrupted STN control in PD
460 would probably have an impact on the SC and PBN and their role in sensory signal
461 processing.

462

463 In addition to demonstrating that STN neurons process nociceptive information, we also
464 assessed whether two subcortical sensori-motor structures from the brain stem transmit
465 nociceptive signals to the STN. Despite SC nociceptive responses having shorter latencies
466 than those of STN neurons to the same stimulus, chemical suppression and lesions of SC had
467 relatively minor effects on the responses of STN to noxious footshock. Lesions of the SC with
468 acid ibotenic reduced the number of cells that do not respond to noxious stimulation,
469 suggesting that the SC gates the pool of responding cells in the STN. Our previous work has
470 demonstrated that the SC is a critical relay for short-latency visual input to DA neurons
471 (Dommett et al., 2005) but not for short-latency nociceptive input (Coizet et al., 2006),
472 transmitted by the PBN (Coizet et al., 2010). The current results suggest the same
473 organization when considering visual and nociceptive input to the STN. The SC is a crucial
474 structure to transmit visual information while the PBN strongly contributes to the relay of
475 nociceptive signals. PBN lesions significantly reduced the number of STN cells responding to

476 noxious stimuli, sparing a group of cells with short latency short duration responses (figure
477 7C), possibly activated by nociceptive information relayed by the thalamus (Dostrovsky,
478 2000a). This nociceptive network linked to the STN is the likely substrate underlying the
479 successful analgesic effects of STN deep brain stimulation. Kim et al (2012) hypothesized that
480 STN DBS improves secondary pain symptoms in PD because this stimulation decreases the
481 abnormally increased muscle tone in patients and may alleviate the primary nociception
482 processing in the central nervous system. DBS effects are complex and despite the success of
483 DBS in treating a variety of psychiatric and neurological disorders, the mechanisms
484 underpinning its therapeutic efficacy remain unclear (McIntyre et al., 2004; Ashkan et al.,
485 2017). DBS is hypothesized to induce a 'functional lesion' of the STN (Follett, 2000), via
486 depolarization blockade and synaptic inhibition (Beurrier et al., 2001; Dostrovski et al.,
487 2000b), that would lead to a suppression the activity of STN neurons. We hypothesize that
488 these mechanisms would reduce the pathologically increased firing rate in the STN in PD
489 (and thus the pain symptoms), as well as nociceptive responses.

490

491 Our current work using anterograde tract tracing neuroanatomy coupled with 3D
492 reconstruction indicates that a small ascending bundle leaves PBN and then splits into three
493 massive projections traveling toward the SC, the thalamus and the SNc/STN. Some fibers
494 from this last ascending pathway continue rostrally to terminate in the amygdala and the
495 cortex. Comparison of the size of the bundle leaving the PBN and the size of the bundles
496 traveling to their targets indicate that the number of labelled fibers clearly increase,
497 suggesting that PBN axons have collaterals. This PBN-STN projection is possibly
498 interconnected with other PBN efferents, such as the PBN – amygdala projection, which
499 partly travels through the STN and has similar types of cells of origin as the PBN cells

500 projecting to STN (Sarhan et al., 2005). With DBS effect on axons and fibers (Chiken and
501 Nambu, 2014), the characterization of this projection and network are important in the
502 context of STN DBS on pain symptoms. Overall, STN DBS would impact STN and PBN
503 nociceptive processing but would also modulate PBN-amygdala fibers and possibly other
504 PBN efferents via the collaterals. The effect of STN DBS would therefore impact many
505 aspects of pain such as, for example, pain-related emotional reactions when activating the
506 PBN-amygdaloid connection or neuroendocrine homeostatic regulation in response to pain
507 with the PBN-hypothalamic pathway (Gauriau and Bernard, 2002). Further experiments are
508 now needed to fully characterize the effect of STN-DBS on nociceptive processing in our rat
509 models and how aspects of that network are modulated to achieve a DBS-related analgesic
510 effect. Pain is a multifaceted experience that can be understood in terms of somatosensory,
511 affective and cognitive dimension. DBS therapies focused on a single facet of pain, originally
512 targeting either somatosensory networks or more recently targeting affective regions
513 (Shirvalkar et al., 2018). The STN is a small structure with functional territories such as
514 limbic, cognitive and sensory, in close proximity to each other. This would allow the
515 potential modulation of different modalities of pain and in the future the best DBS electrode
516 placements within those territories would have to be tested to maximize the analgesic
517 effect. Finally, numerous non motor symptoms can worsen or improve depending on the
518 electrical stimulation parameters, as well as the location of the electrode (i.e. Kim et al.,
519 2015). The best parameters of stimulation for nociception would need to take into account
520 the effect of those parameters on other symptoms of PD.

521

522 Finally, non-neuropathic pain, recently recognized as a frequent and disabling symptom in
523 PD, is a complaint from many patients suffering from numerous neurodegenerative disease

524 such as Alzheimer's disease and other dementias, motor neuron disease, Huntington's
525 disease, spinocerebellar ataxia and spinal muscular atrophy (de Tommaso et al., 2016). Our
526 findings on the involvement of the STN in nociceptive processing and its link to a nociceptive
527 network open a new direction for research to explore a possible role of this structure in
528 other pain syndromes, especially extra-pyramidal ones like Huntington's disease,
529 characterized by a dysfunction of the BG. It also opens up the possibility of developing
530 therapeutic strategies using DBS. A variety of brain sites have been identified for chronic
531 stimulation procedures to attenuate pain (Davis et al., 1998). These targets include the
532 thalamus, the periventricular gray nucleus, the cingulate cortex and the motor cortex
533 (Gorecki et al., 1989, Davis et al., 2000). With the involvement of the STN in a nociceptive
534 network as demonstrated in our work, the STN-DBS technique can thus be considered in the
535 future as a new target for the treatment of pain in pharmaco-resistant patients suffering
536 from previously described neurodegenerative disease, but also, for example, in chronic pain
537 disease or pharmaco-resistant patients with certain form of migraine which have been
538 shown to activate the STN (Schwedt et al., 2014).

539

540 **METHODS**

541 **Electrophysiology - Animals:** Fifty male Hooded Lister rats (265-450g) were anaesthetised
542 with an intra-peritoneal injection of urethane (ethyl carbonate; 1.25g/kg as a 25% aqueous
543 solution) and mounted in a stereotaxic frame with the skull level. Body temperature was
544 maintained at 37°C with a thermostatically controlled heating blanket. Two stainless steel
545 electrodes (E363-1, Plastics One, Roanoke, VA) were inserted into the left hindpaw, one
546 under the skin of the plantar surface of the foot and the other under the skin of the medial
547 aspect of the lower leg/ankle. Craniotomies were then performed to allow access to the STN

548 and SC or PBN. In accordance with the policy of Lyon1 University, the Grenoble Institut des
549 Neurosciences (GIN) and the French legislation, experiments were done in compliance with
550 the European Community Council Directive of November 24, 1986 (86/609/EEC). The
551 research was authorized by the Direction Départementale des Services Vétérinaires de
552 l'Isère – Ministère de l'Agriculture et de la Pêche, France (Coizet Véronique, PhD, permit
553 number 381003). Every effort was made to minimize the number of animals used and their
554 suffering during the experimental procedure. All procedures were reviewed and validated by
555 the "Comité éthique du GIN n°004" agreed by the research ministry (permits number 309
556 and 310).

557

558 **Electrophysiology - STN recordings:** Extracellular single unit recordings were made from STN
559 neurons located contralaterally to the stimulated hindpaw, using glass microelectrodes
560 pulled via a vertical electrode puller (Narashige Laboratory Instruments Ltd. Tokyo, Japan)
561 and broken back to a tip diameter of approximately 1 μm (impedances 5-20 M Ω , measured
562 at 135 Hz in 0.9% NaCl). Electrodes were filled with 0.5 M saline and 2% Pontamine Sky Blue
563 (BDH Chemicals Ltd., Poole, UK). The electrode was lowered into the STN (3.6-4.16 mm
564 caudal to bregma, 2.0-3.0 mm lateral to midline, 6.8-8.20 mm ventral to the brain surface
565 according to the atlas Paxinos and Watson (2005) with a hydraulic microdrive (Trent Wells
566 Inc.). The STN electrode was lowered until a putative STN neuron was identified on the basis
567 of several criteria: 1) the pattern of activity while lowering the electrode, which was as
568 follows: an initial absence of activity corresponding to the medial lemniscus fibre track was
569 followed shortly after by large amplitude, fast bursty neurons located in zona incerta and
570 then a second absence of action potentials. The return of activity corresponded to the STN;

571 2) STN firing rate between 8.5 to 14.7 Hz (Hassani et al., 1996; Kreiss et al., 1996) and 3) STN
572 firing pattern described as irregular or bursting (Hamani et al., 2004).

573

574 SC/PBN recording and muscimol experiments: Extracellular multiunit recordings were made
575 simultaneously from the SC or PBN ipsilateral to the STN recording electrode using a
576 tungsten electrode coupled to a 30-gauge stainless steel injector filled with muscimol (0.25
577 $\mu\text{g}/\mu\text{l}$ in saline, Sigma-Aldrich). An angled approach was used in the PBN, with the electrode
578 tilted caudally by 35° , entering the brain at 11.4 mm caudal to bregma and 1.9-2.0 mm
579 lateral to midline. PBN was encountered 5.2-5.8 mm below the brain surface. In a second
580 group of rats, the electrode/injector assembly was introduced vertically into the SC (AP: 6.2-
581 6.5 mm, bregma; ML: 2.1-2.2 mm, bregma; DV: 4.2-4.5 mm, brain surface). The
582 electrode/injector assembly was lowered into the SC into the lateral part of the deep layers
583 of the SC, known to project to the STN (Coizet et al., 2009).

584

585 Microinjections were made (0.5 μl at a rate of 0.5 $\mu\text{l}/\text{min}$) via a 10 μl Hamilton syringe
586 mounted on an infusion pump, connected to the injector by a length of plastic tubing.
587 Extracellular voltage excursions were amplified, band-pass filtered (300 Hz-10 kHz), digitized
588 at 10 kHz and recorded directly onto computer disc using a Micro 1401 data acquisition
589 system (Cambridge Electronic Design [CED] Systems, Cambridge, UK) running CED data
590 capture software (Spike 2).

591

592 **Electrophysiology - Stimulation procedure:** As previously described (Coizet et al., 2006;
593 2010), PBN and SC neurons were identified by their response to noxious footshocks induced
594 by single pulses (0.5 Hz, 2 ms duration) at an intensity of 5.0 mA. The activity of the cells

595 (single unit in STN and multiunit activity in the PBN or SC) was recorded during a control
596 period (120 trials of sham stimulation) and during the application of noxious footshocks (120
597 trials). For the muscimol experiments, an injection of muscimol was made into the PBN or
598 SC. Typically, a change in local SC/PBN multiunit activity was seen within 60-120 s of the
599 injection. Noxious electrical footshock stimulation was applied throughout this period, until
600 either the effects of the drug wore off in the SC/PBN, or the STN cell was lost. After a
601 complete trial, further STN neurons were tested in the same way. Between 1 and 5 STN cells
602 were tested in a single subject.

603

604 **Nociceptive nature of the stimulation**

605 The electrical stimulation parameters from 3 to 5 mA have previously been shown to be
606 approximately three times the threshold for activating C-fiber (Chang and Shyu, 2001;
607 Matthews and Dickenson, 2001; Carpenter et al., 2003), to produce reliable A δ and C-fiber
608 responses in the anesthetized rat spinal cord (Urch et al., 2003) and c-fos expression in the
609 nociceptive superficial lamina of the spinal cord (Coizet et al., 2006). They also activate the
610 SC (Coizet et al., 2006), the PBN (Coizet et al., 2010) and the dopaminergic neurons (Coizet et
611 al., 2006, 2010) in a qualitatively similar way than a mechanical noxious pinch with a teathed
612 forceps.

613 To ascertain the noxious nature of our stimulation, we performed three control tests based
614 on the previous observations. i) We first performed an intensity test on a group of STN cells
615 following footshocks with intensities ranging from 0 to 5 mA. Among the 17 STN neurons
616 responding to the maximum 5 mA stimulation, a decrease of intensity was followed by a
617 decrease of the number of responding cells following a 4 mA (n = 12) and a 3 mA (n = 7)
618 stimulation. None of those cells showed a response for intensities under the threshold of 3

619 mA (figure 10A, supplementary results). Furthermore, analysis performed on the 7 cells
620 responding to 3, 4 and 5 mA showed a significant effect of the intensity of the stimulation
621 when considering the maximum amplitude (ANOVA – repeated measure: $F [2,20] = 11.51, p$
622 < 0.01) and the magnitude (ANOVA – repeated measure : $F[2,20] = 17.55, p < 0.001$): in both
623 cases there was a significant increase in the response parameters with the increase in the
624 intensity (Tukey-Kramer post-hoc comparison – maximum amplitude: 3 mA vs 5 mA, $p <$
625 0.01 , 4mA vs 5 mA, $p < 0.05$; magnitude: 3 mA vs 4 mA, $p < 0.05$; 3 mA vs 5 mA, $p < 0.001$). ii)
626 We compared the effect of a mechanical pinch with a teethered forceps and a 5 mA footshock
627 on STN neuron responses. All the cells responding to the manual pinch showed a
628 qualitatively similar excitation to the footshock (figure 10B, supplementary results), while
629 none of the cells unresponsive to pinch were activated by footshock. iii) As previously
630 reported (Coizet et al., 2006, 2010), noxious footshock of 5mA for an hour induced the
631 expression of c-fos labeling within the medial part of the ipsilateral superficial layers of the
632 lumbar cord, especially layers I and II, although layers III-V also contained some labeling. In
633 control animals, where electrodes were implanted but the stimulation was not delivered,
634 substantially lower levels of c-fos were observed (figure below D). These results confirm that
635 the footshock used in the present study was activating nociceptive elements in the lumbar
636 spinal cord (Besson, 1987; Almeida et al., 2004) consistent with known somatotopic
637 representations of the hindfoot; i.e. primary afferents from the foot terminate medially
638 (Sweet and Woolf, 1985).

639

640 **Electrophysiology - Histology and analysis:** The position of SC and PBN recording sites were
641 marked with a small lesion caused by passing 10 μ A DC current for 2.5 min through the
642 tungsten recording electrode. The final recording site for the STN recording electrode was

643 marked by passing a constant cathodal current of 27.5 μ A (constant current source) through
644 the electrode for a period of 30 min to eject Pontamine Sky Blue. Animals were then killed
645 by an overdose of pentobarbital and perfused with 0.9 % saline followed by 4 %
646 paraformaldehyde. Brains were removed and postfixed overnight in 4% paraformaldehyde
647 at 4 °C, before being transferred into sucrose for 36 h. Serial coronal (30 μ m) sections were
648 cut, mounted on slides and processed with a Nissl stain (Cresyl Violet). Once sections had
649 been processed, recording sites were reconstructed onto sections taken from the atlas of
650 Paxinos and Watson (2005).

651

652 Peri-stimulus time interval histograms (PSTHs) were constructed based on SC/PBN multi-unit
653 (bin width 1 ms) and STN single-unit data (bin width 10 ms). PSTHs were imported into an
654 Excel program (Peter Furness, University of Sheffield, Coizet et al., 2006, 2009, 2010;
655 Dommett et al., 2005) which determined the following response characteristics: i) Baseline
656 activity: was the mean number of single- multi-unit events during the 500 ms bins prior to
657 the footshock. ii) Response latency: The latency of a visually-evoked response was marked as
658 the point when the value of post-stimulation events exceeded 1.96 S.D. of the baseline
659 mean. (iii) Response duration: Response offset was recorded when post-stimulation activity
660 returned to a value 1.96 S.D. of the baseline mean. iii) Amplitude of the response is the
661 maximum amplitude during the response. iv) Magnitude of the response: is the mean
662 number of single- multi-unit events between response onset and offset minus the baseline
663 mean.

664

665 **Lesion procedure in SC and PBN**

666 Fourteen rats received a unilateral ibotenic acid lesion of the SC or the PBN. Each rat was
667 anesthetized with isofluorane (5 % for the induction and 1-2 % for maintenance) and placed
668 in a stereotaxic instrument. A 30-gauge metal injector needle filled with ibotenic acid (20
669 $\mu\text{g}/\mu\text{l}$ in phosphate buffered saline) was introduced using the same coordinates as for the
670 electrophysiological procedure. The injections in the PBN were made according to a
671 previously published procedure by Reilly and Trifunovic (2000; 2001) with
672 electrophysiological guidance to improve the accuracy of the location of the lesion. The
673 microinjections were made (0.5 $\mu\text{l}/\text{min}$) in the SC (0.5-0.65 μl) and the PBN (0.3-0.5 μl) as for
674 the muscimol injections (see above). The cannula remained in situ for a further 10 min to
675 minimize the spread of neurotoxin back along the track before the cannula was removed
676 and the incision was closed.

677

678 **Lesion procedure in STN and hot plate test**

679 Twenty Long Evans rats were anesthetized with ketamine (100 mg/Kg, s.c., Imalgène 1000,
680 Merial, Lyon, France) and medetomidine (0,85 mg/Kg, s.c., Domitor, Orion Pharma, Espoo,
681 Finland). Rats were secured in Kopf stereotaxic apparatus. Then, a unilateral 30-gauge
682 stainless-steel injector needle connected by Tygon tubing (Saint Gobain performance
683 pastics) with a 10 μL Hamilton microsyringe (Bonaduz, Switzerland) fixed on a micropump
684 (CMA, Kista, Sweden) was positioned into the STN. Coordinates for the aimed site were (with
685 tooth bar set at -3.3mm): anteroposterior -3.72mm; lateral $\pm 2.4\text{mm}$ from bregma;
686 dorsoventral -8.4mm from skull (Paxinos & Watson, 2005). Rats received either a bilateral
687 injection of ibotenic acid (9.4 $\mu\text{g}/\mu\text{L}$, AbCam Biochemical, Cambridge, UK; STN-lesioned
688 group, n=12) or vehicle solution (phosphate buffer, 0.1M; Sham control group, n=8). The
689 volume injected was 0.5 μL per side infused over 3 min. The injectors were left in place for 3

690 min to allow diffusion. At the end of surgery, medetomidine was reversed by 0.2 mg (4.28
691 mg/kg, s.c.) atipamezole (Antisedan, Orion Pharma, Espoo, Finland). Three weeks after the
692 surgery, all the animals performed the hot plate test. Each rat was placed on a heated metal
693 plate (53°) surrounded by a transparent cylinder. The experimenter was constantly watching
694 the rat's behaviour during the test to measure the latency of the first sign of paw licking or
695 jumping and to quickly remove the animals from the apparatus. The maximum time on the
696 hot place was set to 30 s. The rat's behaviour was also video recorded online on the
697 computer for a second finer analysis.

698

699 **6-OHDA lesions**

700 Rats were anaesthetised with an intraperitoneal injection of a mixture of ketamine-xylazine
701 (0.765/1.1 ml; 1 ml/kg, i.p.) and placed in a stereotaxic frame with the skull level. All the
702 microinjections were made via a sharpened 30G injection cannula connected with
703 polyethylene tubing to a 10- μ l Hamilton syringe driven by an infusion pump (0.5 μ l/min).
704 After the injection, the cannula was left in place for a further 5 min to allow diffusion.
705 Animals were divided into two groups: i) A group with a total dopaminergic lesion (n = 9), in
706 which 3 μ l of 6-OHDA (Sigma-Aldrich, 3 mg/ml in sterile 0.9% NaCl and 0.1% ascorbic acid)
707 was injected into the left SNc using the following stereotaxic coordinates: AP: + 3.0 mm; ML :
708 + 2.1 mm and DV: + 2.4 mm from interaural zero mm; ii) A control group with no injection of
709 the toxin (n = 9).

710 The extent of the DA denervation following the 6-OHDA injections in the SNc was
711 determined using tyrosine hydroxylase (TH) immunohistochemistry. To reveal TH, the
712 sections were washed and incubated in a blocking solution containing 0.1M PB with 0.3% of
713 triton X-100 (TX), 2.5% of Bovine Serum Albumin (BSA) and 5% normal horse serum (NHS) for

714 2 h before being transferred overnight in a 0.1M PB-TX 0.3% with 1% BSA and 2% NHS
715 containing the primary mouse monoclonal TH antibody, diluted 1:3000 (Chemicon,
716 Hampshire, UK). The following day, sections were washed in 0.1M PB and incubated with the
717 secondary antibody, biotinylated antimouse made in horse (in a dilution of 1:1000 in 0.1M
718 PB-TX 0.3% with 2% NHS) for 2 h. Following further washes in 0.1M PB, the sections were
719 exposed to the elite Vectastain ABC reagent (Vector Laboratories, Burlingame, CA, USA)
720 diluted 1:100 in PB-TX 0.3%, for 2 h. Again following washes in 0.1M PB, immunoreactivity
721 was revealed by exposure to VIP (Vector Laboratories) for 2 min which produced a purple
722 reaction product. Sections were then mounted onto gelled slides, dehydrated through
723 alcohols and cleared in xylene before being coverslipped with DPX. TH-immunolabelling of
724 DA neurons and terminals was evaluated using a light microscope (Nikon, Eclipse 80i,
725 TRIBVN, Chatillon, France) coupled to the ICS Framework computerized image analysis
726 system (TRIBVN, 2.9.2 version, Chatillon, France). For quantification, TH-labeled coronal
727 sections of SNc (AP -5.3 mm to -5.8 mm from Bregma) and striatum (AP 0.20 mm to -0.30
728 mm from bregma) were digitized using a Pike F-421C camera (ALLIED Vision Technologies
729 Stradtroda, Germany). Optical densities (OD) were measured for the denervated and non-
730 denervated territories of the lesioned animals for each section and were compared to those
731 in the homologous regions of the sham-operated animals.

732

733 **Statistics**

734 The statistical reliability of differences between response latencies for the SC/PBN and STN,
735 and comparisons of response duration, amplitude and magnitude before and after SC/PBN
736 injections of muscimol was made using parametric (ANOVA, t-test) or non-parametric
737 (Wilcoxon, Mann-Whitney) statistical tests according to the normality of the data. STN

738 baseline firing rate change before and after the noxious stimulation was assessed during the
739 500 ms before the sham and noxious stimulation. The data were imported in MATLAB, binned
740 and compared using a Wilcoxon test. STN firing pattern was also assessed using MATLAB
741 according to the methodology developed by Piallat et al. (2001). Neurons were classified as
742 irregular, regular or bursting according to the interspike distributions and autocorrelograms.
743 Burst activity showed a wide or bimodal interval interspike distribution and a significant
744 single peak on the autocorrelation function. Irregular activity was characterised by a wide
745 interval interspike distribution and a flat autocorrelogram. Regular activity was characterised
746 by a narrow interval interspike distribution and an autocorrelogram with multiple regular
747 peaks.

748

749 **Anatomy -animals:** We used 14 male Long Evans rats (350-460 g, Janvier, France). Animals
750 were anaesthetised with an intraperitoneal injection of a mixture of Ketaset (0.765 ml/kg)
751 and Rompun (1.1 ml/kg).

752

753 **Anatomy - anterograde experiment:** Single injections of the anterograde tracers
754 biotinylated dextran amine (BDA: Sigma-Aldrich) or Phaseolus vulgaris leucoagglutinin (PHA-
755 L: Vector Laboratories, Peterborough, UK) were made into the PBN. An angled approach was
756 used as previously described (Coizet et al., 2010). BDA (10 % in phosphate buffer; PB) was
757 pressure ejected in volumes of 30-90 nl via a glass micropipette (20 μ m diameter tip) using a
758 compressed air injection system, while PHA-L was ejected iontophoretically (5 μ A anodal
759 current applied to a 2.5 % solution in PB, 7 s on/off for 15-20 min).

760

761 **Anatomy - retrograde experiment:** Small (10-20 nl) pressure injections of the retrograde
762 tracers Cholera toxin subunit B (CTB, 1 % solution in phosphate buffer) or the fluorescent
763 tracer Fluorogold (FG, 4 % in distilled water) were made into the STN. After allowing 7 days
764 for the transport of tracers, animals were re-anesthetised with pentobarbitane and perfused
765 transcardially. The brains were placed immediately in 4 % PFA overnight before being
766 cryoprotected by immersion in sucrose solution (20% in 0.1 M PB) for at least 36 hours.
767 Three series of coronal or sagittal sections (30 µm) were cut on a freezing microtome and
768 collected in 0.1 M PB for further immunohistochemistry processing, except for tissue
769 containing FG where one series was collected directly onto slides, allowed to dry in a light
770 protected box and coverslipped with DPX mountant.

771

772 **Anatomy – histology:** To reveal the tracers, (BDA, PHA-L, CTB), free-floating sections were
773 washed with 0.1 M PB followed by 0.1 M PB containing 0.3 % Triton X-100 (PB-TX) for 30
774 min. For animals injected with PHA-L or CTB, the sections were incubated overnight in
775 primary antibody solution (goat anti-PHA-L, 1:1,000 dilution, Vector, or goat anti-CTB,
776 1:4,000 dilution, Quadrantech). The next day, sections were washed with PB-TX and
777 incubated for 2 h in biotinylated rabbit anti-goat IgG (1:100, Vector, in PB-TX containing 2 %
778 normal rabbit serum). After 30 min washing, all the sections were incubated in Elite
779 Vectastain ABC reagent (Vector, 1:100 in PB-TX) for 2 h. The peroxidase associated with the
780 tracers was revealed by reacting tissue with H₂O₂ for approximately 1 min using nickel-
781 enhanced diaminobenzidine (DAB) as the chromogen for BDA and CTB (black reaction
782 product) and using nickel-free DAB for PHA-L (brown reaction product). Finally, sections
783 were washed in PB, mounted on gelatine-coated slides, dehydrated in graded dilutions of
784 alcohol, cleared in xylene and coverslipped in DPX.

785

786 **Anatomy – analysis:** Following injections of anterograde tracers into the PBN, three coronal
787 sections through the STN separated by ~ 0.5 mm (equivalent to -3.6, -3.8 and -4.1 mm caudal
788 to bregma in the atlas of Paxinos and Watson, 2005) or three sagittal sections (equivalent to
789 1.9, 2.4 and 2.9 lateral to bregma) were selected for analysis. Sections of interest were
790 digitized using a light microscope (Nikon, Eclipse 80i, TRIBVN, 2.9.2 version, Chatillon,
791 France) coupled to the ICS Framework computerized image analysis system (TRIBVN, 2.9.2
792 version, Chatillon, France) and a Pike F-421C camera (ALLIED Vision Technologies Stradtroda,
793 Germany).

794 The location of retrogradely labelled cells was plotted on four coronal sections through the
795 PBN separated by ~ 0.5 mm (equivalent to -8.8, -9.3, -9.8 caudal to bregma). A series of
796 digital images (magnification 10 X) were taken and imported into a graphics program
797 (Macromedia Freehand) where they were montaged. The borders and layers of the PBN
798 were drawn over the montage. The location of anterogradely labelled axons and terminals
799 was plotted on sagittal sections from 1.9 to 2.9 lateral from bregma. Fibres and terminals
800 associated with the injections were traced with the aid of a pen tablet (intuos) with a
801 microscope equipped with a camera lucida and a graphics program (Microsoft PowerPoint).
802 By focusing on different depths in the brain sections, it was possible to produce a drawing
803 that contained all labelled elements in the section.

804

805 For the 3D reconstruction, the most representative example was selected and series of
806 sagittal sections containing PBN and STN were digitized using a light microscope (Nikon,
807 Eclipse 80i, TRIBVN, 2.9.2 version, Chatillon, France) coupled to the ICS Framework
808 computerized image analysis system (TRIBVN, 2.9.2 version, Chatillon, France) and a Pike F-

809 421C camera (ALLIED Vision Technologies Stradtroda, Germany). Digitized images were
810 converted into a .tiff format and individually exported in Adobe Photoshop to create
811 individual .tiff files with the same dimension. A stack of 2D sagittal sections was then created
812 using Cygwin (Cygwin TM sources) and IMOD package software (Boulder laboratory for 3D
813 Electron Microscopy of Cells, University of Colorado, Boulder, CO) (Kremer et al., 1996). As
814 previously described (Coizet et al., 2017; Maily et al., 2010), sections were aligned with the
815 Midas program from IMOD using manual rigid body transformations. The stack was opened
816 in IMOD, where the structures of interest were delineated including the PBN, SNr / SNC, STN,
817 and SC. The injection site and individual ascending labelled axons were drawn in IMOD
818 directly on the digitized images. This process also created a 3D reconstruction of ascending
819 fibers.

820

821 Acknowledgement: The Photonic Imaging Center of Grenoble Institute Neuroscience (Univ
822 Grenoble Alpes – Inserm U1216) is part of the ISdV core facility and certified by the IBISA
823 label. Région Rhône-Alpes

824

825 Conflicts of interest: The authors have declared that no conflict of interest exists.

826

827 REFERENCES

828 **The functional anatomy of disorders of the basal ganglia**

829 RL Albin, AB Young and JB Penney (1995)

830 *Trends in Neuroscience* **18(2)**: 63-64.

831

832 **Parallel organization of functionally segregated circuits linking basal ganglia and cortex**

833 GE Alexander, MR DeLong and PL Strick (1986)

834 *Annual Review of Neuroscience* **9**: 357-381.

835

836 **Afferent pain pathways: a neuroanatomical review**

837 TF Almeida, S Roizenblatt and S Tufik (2004)

838 *Brain Research* **1000**: 40-56.

839 DOI: 10.1016/j.brainres.2003.10.073

840

841 **Insights into the mechanisms of deep brain stimulation**

842 K Ashkan, P Rogers, H Bergman and I Ughratdar (2017)

843 *Nature Reviews. Neurology* **13**: 548-554.

844 DOI: 10.1038/nrneurol.2017.105

845

846 **Six questions on the subthalamic nucleus: lessons from animal models and from
847 stimulated patients. Neuroscience**

848 C Baunez, J Yelnik and L Mallet (2011)

849 *Neuroscience* **198**: 193-204.

850 DOI: 10.1016/j.neuroscience.2011.09.059.

851

852 **The Effects of Mechanical and Thermal Stimuli on Local Field Potentials and Single Unit
853 Activity in Parkinson's Disease Patients**

854 A Belasen, Y Youn, L Gee, J Prusik, B Lai, A Ramirez-Zamora, K Rizvi, P Yeung, DS Shin, C
855 Argoff and JG Pilitis (2016)

856 *Neuromodulation* **19(7)**: 698-707.

857 DOI: 10.1111/ner.12453.

858

859 **Response inhibition rapidly increases single-neuron responses in the subthalamic nucleus
860 of patients with Parkinson's disease**

861 D Benis, O David, B Piallat, A Kibleur, L Goetz, M Bhattacharjee, V Fraix, E Seigneuret, P
862 Krack, S Chabardès and J Bastin (2016)

863 *Cortex* **84**: 111-123.

864 DOI: 10.1016/j.cortex.2016.09.006.

865

866 **Pathophysiology of pain and fatigue in Parkinson's disease**

867 A Berardelli, A Conte, G Fabbrini, M Bologna, A Latorre, L Rocchi and A Suppa (2012)

868 *Parkinsonism & Related Disorders* **18 Suppl 1**: S226-8.

869 DOI: 10.1016/S1353-8020(11)70069-4.

870

871 **The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism**

872 H Bergman, B Wichmann, B Karmon and R DeLong (1994)

873 *Journal of Neurophysiology* **72**: 507–520.

874 DOI: 10.1152/jn.1994.72.2.507.

875

876 **A possible spino (trigemino)-ponto-amygdaloid pathway for pain**

877 JF Bernard, M Peschanski and JM Besson (1989)

878 *Neuroscience Letters* **100(1-3)**: 83-88.

879

880 **Peripheral and spinal mechanisms of nociception**

881 JM Besson (1987)

882 *Physiological Reviews* **67**:67-187.

883

884 **High-frequency stimulation produces a transient blockade of voltage-gated currents in subthalamic neurons**

886 C Beurrier, B Bioulac, J Audin and C Hammond (2001)

887 *Journal of Neurophysiology* **85**: 1351-6.

888 DOI: 10.1152/jn.2001.85.4.1351

889

890 **Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease**

892 C Brefel-Courbon, F Ory-Magne, C Thalamas, P Payoux and Rascol O (2013)

893 *Parkinsonism & Related Disorders* **19(5)**: 548-52.

894 DOI: 10.1016/j.parkreldis.2013.02.003.

895

896 **The good and bad differentially encoded within the subthalamic nucleus in rats**

897 E Breyse, Y Pelloux, C Baunez (2015)

898 *eNeuro* **15**: 2(5).

899 DOI: 10.1523/ENEURO.0014-15.2015.

900
901 **Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde**
902 **horseradish peroxidase study in the rat**
903 NS Canteras, SJ Shammah-Lagnado, BA Silva and JA Ricardo (1990)
904 *Brain Research* **513(1)**: 43-59.
905
906 **Disrupting neuronal transmission: mechanism of DBS?**
907 S Chiken and A Nambu (2014)
908 *Frontiers in Systems Neuroscience* **8**: 33.
909 DOI: 10.1111/ejn.12711.
910
911 **The role of the basal ganglia in nociception and pain**
912 EH Chudler and WK Dong (1995)
913 *Pain* **60(1)**: 3-38.
914
915 **Nociceptive responses of dopaminergic neurones modulated by experimental**
916 **manipulations of the superior colliculus in rat**
917 V Coizet, E Dommett, PG Overton and P Redgrave (2006)
918 *Neuroscience* **139(4)**: 1479-1493.
919 DOI: 10.1016/j.neuroscience.2006.01.030
920
921 **Short-latency visual input to the subthalamic nucleus is provided by the midbrain superior**
922 **colliculus**
923 V Coizet, J Graham, J Moss, P Bolam, M Savasta, J McHaffie, P Redgrave and P Overton
924 (2009)
925 *Journal of Neuroscience* **29(17)**: 5701-09.
926 DOI: 10.1523/JNEUROSCI.0247-09.2009.
927
928 **The parabrachial nucleus is a critical link in the transmission of short latency nociceptive**
929 **information to midbrain dopaminergic neurons**
930 V Coizet, EJ Dommett, EM Klop, P Redgrave and PG Overton (2010)
931 *Neuroscience* **168(1)**: 263-72.

932 DOI: 10.1016/j.neuroscience.2010.03.049.

933

934 **The Rat prefronto-striatal and prefronto-thalamic bundles analysed in 3D: Evidence for a**
935 **topographical organization**

936 V Coizet, S Heilbronner, C Carcenac, P Mailly, J Lehman, M Savasta, O David, JM Deniau, HJ
937 Groenewegen and SN Haber (2017)

938 *Journal of Neuroscience* **37(10)**: 2539-2554.

939 DOI: 10.1523/JNEUROSCI.3304-16.2017.

940

941 **Pathophysiology of somatosensory abnormalities in Parkinson disease**

942 A Conte, N Khan, G Defazio, JC Rothwell and A Berardelli (2013)

943 *Nature Reviews. Neurology* **9(12)**: 687-97.

944 DOI: 10.1038/nrneurol.2013.224.

945

946 **Distribution of brainstem projections from spinal lamina I neurons in the cat and the**
947 **monkey**

948 AD Craig (1995)

949 *Journal of Comparative Neurology* **361**: 225–248.

950 DOI: 10.1002/cne.903610204

951

952 **Effects of deep brain stimulation on pain and other non-motor symptoms in Parkinson**
953 **disease**

954 RG Cury, R Galhardoni, ET Fonoff, MG Dos Santos Ghilardi, F Fonoff, D Arnaut, ML
955 Myczkowski, MA Marcolin, E Bor-Seng-Shu, ER Barbosa, MJ Teixeira and D Ciampi de
956 Andrade (2014) *Neurology* **83(16)**: 1403-9.

957 DOI: 10.1212/WNL.0000000000000887.

958

959 **Brain targets for pain control**

960 KD Davis, AM Lozano, RR Tasker and JO Dostrovsky (1998)

961 *Stereotactic and functional neurosurgery* **71**: 173-179.

962 DOI: 10.1159/000029661

963

964 **Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron**
965 **emission tomography study**

966 E Dellapina, A Gerdelat-Mas, F Ory-Magne, L Pourcel, M Galitzky, F Calvas, M Simonetta-
967 Moreau, C Thalamis, P Payoux and C Brefel-Courbon (2011)

968 *Movement Disorders* **26(1)**: 153-157.

969 DOI: 10.1002/mds.23406

970

971 **The lamellar organization of the rat substantia nigra pars reticulata – distribution of**
972 **projection neurons**

973 JM Deniau and G Chevalier (1992)

974 *Neuroscience* **46**: 361–377.

975

976 **Quantitative measurement of pain sensation in patients with Parkinson disease**

977 R Djaldetti, A Shifrin, Z Rogowski, E Sprecher, E Melamed and D Yarnitsky (2004)

978 *Neurology* **62**: 2171-2175.

979

980 **How visual stimuli activate dopaminergic neurons at short latency**

981 E Dommett, V Coizet, CD Blaha, J Martindale, V Lefebvre, N Walton, JEW Mayhew, PG

982 Overton and P Redgrave (2005)

983 *Science* **307**, 1476-1479.

984 DOI: 10.1126/science.1107026

985

986 **Role of thalamus in pain**

987 JO Dostrovsky (2000a)

988 *Progress in brain research* **129**: 245-257.

989 DOI: 10.1016/S0079-6123(00)29018-3.

990

991 **Microstimulation-induced inhibition of neuronal firing in human globus pallidus**

992 JO Dostrovsky, R Levy, JP Wu, WD Hutchinson, RR Tasker and AM Lozano (2000b)

993 *Journal of Neurophysiology* **84(1)**: 570-4.

994 DOI: 10.1152/jn.2000.84.1.570

995

- 996 **The surgical treatment of Parkinson's disease**
997 KA Follett (2000)
998 *Annual Review of Medicine* **51**: 135-147.
999 DOI: 10.1146/annurev.med.51.1.135
1000
- 1001 **Response characteristics of subthalamic neurons to the stimulation of the sensorimotor**
1002 **cortex in the rat**
1003 K Fujimoto and H Kita (1993)
1004 *Brain Research* **609(1-2)**: 185-92.
1005
- 1006 **Pain pathways and parabrachial circuits in the rat**
1007 C Gauriau and JF Bernard (2002)
1008 *Experimental Physiology* **87**: 251-258.
1009
- 1010 **Thalamic stimulation and recording in patients with deafferentation and central pain**
1011 J Gorecki, T Hirayama, JO Dostrovsky, RR Tasker and FA Lenz (1989)
1012 *Stereotactic and Functional Neurosurgery* **52(2-4)**:219-26.
1013 DOI: 10.1159/000099504.
1014
- 1015 **A computational model of action selection in the basal ganglia. I. A new functional**
1016 **anatomy**
1017 K Gurney, TJ Prescott and P Redgrave (2001)
1018 *Biological Cybernetics* **84**: 401-410.
1019 DOI: 10.1007/PL00007984.
1020
- 1021 **Pain in Parkinson's disease**
1022 AD Ha and J Jankovic (2011).
1023 *Movement Disorders* **27(4)**: 485-91.
1024 DOI: 10.1002/mds.23959.
1025
- 1026 **The subthalamic nucleus in the context of movements disorders**
1027 C Hamani, JA Saint-Cyr, J Fraser, M Kaplitt and AM Lozano (2004)

1028 *Brain* **127**: 4-20.
1029 DOI: 10.1093/brain/awh029.
1030
1031 **Peripheral input to the rat subthalamic nucleus, an electrophysiological study**
1032 C Hammond, JM Deniau, B Rouzaire-Dubois and J Feger (1978)
1033 *Neuroscience Letters* **9(2-3)**: 171-6.
1034
1035 **Pain is common in Parkinson's disease**
1036 Hanagasi HA, Akat S, Gurvit H, Yazici J and Emre M (2010)
1037 *Clinical Neurology and Neurosurgery* **113(1)**: 11-3.
1038 DOI: 10.1016/j.clineuro.2010.07.024.
1039
1040 **Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of**
1041 **disinhibition via the globus pallidus**
1042 OK Hassani, M Mouroux and J Feger (1996)
1043 *Neuroscience* **72**: 105–115.
1044
1045 **Sensory (nociceptive) stimulation evokes Fos expression in the subthalamus of**
1046 **hemiparkinsonian rats**
1047 CE Heise, S Reyes and J Mitrofanis (2008)
1048 *Neurological Research* **30(3)**: 277-84.
1049 DOI: 10.1179/016164107X235455.
1050
1051 **Spinal lamina I projection neurons in the rat: collateral innervation of parabrachial area**
1052 **and thalamus**
1053 JL Hylden, F Anton and RL Nahin (1989)
1054 *Neuroscience* **28(1)**: 27-37.
1055
1056 **A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition**
1057 M Jahanshahi, I Obeso, JC Rothwell and JA Obeso (2015)
1058 *Nature Review Neuroscience* **16(12)**: 719-32.
1059 DOI: 10.1038/nrn4038.

1060

1061 **Chronic subthalamic deep brain stimulation improves pain in Parkinson disease**

1062 HJ Kim, SH Paek, JY Kim, JY Lee, YH Lim, MR Kim, DG Kim and BS Jeon (2008)

1063 *Journal of Neurology* **255(12)**: 1889-94.

1064 DOI: 10.1007/s00415-009-0908-0.

1065

1066 **The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year**
1067 **follow-up study**

1068 HJ Kim, BS Jeon, JY Lee, SH Paek and DG Kim (2012)

1069 *Neurosurgery* **70(1)**: 18-23.

1070 DOI: 10.1227/NEU.0b013e3182266664.

1071

1072 **Cortical inputs to the subthalamus: intracellular analysis**

1073 ST Kitai and JM Deniau (1981)

1074 *Brain Research* **214(2)**: 411-5.

1075

1076 **An update of the impact of deep brain stimulation on non-motor symptoms in Parkinson's**
1077 **disease**

1078 L Klingelhofer, M Samuel, KR Chaudhuri and K Ashkan (2014)

1079 *Journal of Parkinson's Disease* **4(2)**: 289-300.

1080 DOI: 10.3233/JPD-130273.

1081

1082 **In cat four times as many lamina I neurons project to the parabrachial nuclei and twice as**
1083 **many to the periaqueductal gray as to the thalamus**

1084 EM Klop, LJ Mouton, R Hulsebosch, J Boers and G Holstege (2005)

1085 *Neuroscience* **134(1)**: 189-97.

1086 DOI: 10.1016/j.neuroscience.2005.03.035.

1087

1088 **Segregation and convergence of information flow through the cortico-subthalamic**
1089 **pathways**

1090 BP Kolomiets, JM Deniau, P Mailly, A Ménétrey, J Glowinski and AM Thierry (2001)

1091 *Journal of Neuroscience* **21**: 5764-5772.

1092

1093 **Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced**

1094 **Parkinson's disease**

1095 P Krack, A Batir, N Van Blercom, S Chabardes, V Fraix, C Ardouin, A Koudsie, PD Limousin, A

1096 Benazzouz, JF LeBas, AL Benabid and P Pollak (2003)

1097 *The New England Journal of Medicine* **349(20)**: 1925-34.

1098 DOI: 10.1056/NEJMoa035275.

1099

1100 **Apomorphine and dopamine D1 receptor agonists increase the firing rates of subthalamic**

1101 **nucleus neurons**

1102 DS Kreiss, LA Anderson and JR Walters (1996)

1103 *Neuroscience* **72(3)**: 863-76.

1104

1105 **Computer visualization of three-dimensional image data using IMOD**

1106 JR Kremer, DN Mastronarde and JR McIntosh (1996)

1107 *Journal of Structural Biology* **116**: 71-76.

1108 DOI: 10.1006/jsbi.1996.0013.

1109

1110 **Beyond the reward pathway: coding reward magnitude and error in the rat subthalamic**

1111 **nucleus**

1112 S Lardeux, R Pernaud, D Paleressompouille and C Baunez (2009)

1113 *Journal of Neurophysiology* **102(4)**: 2526-2537.

1114 DOI: 10.1152/jn.91009.2008.

1115

1116 **Different populations of subthalamic neurons encode cocaine vs. sucrose reward and**

1117 **predict future error**

1118 S Lardeux, D Paleressompouille, R Pernaud, M Cador and C Baunez (2013)

1119 *Journal of Neurophysiology* **110(7)**: 1497-1510.

1120 DOI: 10.1152/jn.00160.2013.

1121

1122 **Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease**

1123 P Limousin, P Krack, P Pollak, A Benazzouz, C Ardouin, D Hoffmann and AL Benabid (1998)

1124 *The New England Journal of Medicine* **339(16)**: 1105-1111.
1125 DOI: 10.1056/NEJM199810153391603.
1126
1127 **Synchronous Unit Activity and Local Field Potentials Evoked in the Subthalamic Nucleus by**
1128 **Cortical Stimulation**
1129 PJ Magill, A Sharott, MD Bevan, P Brown and JP Bolam (2004)
1130 *Journal of Neurophysiology* **92**: 700-714.
1131 DOI: 10.1152/jn.00134.2004.
1132
1133 **A 3D multi-modal and multi-dimensional digital brain model as a framework for data**
1134 **sharing**
1135 P Mailly, SN Haber, HJ Groenewegen and JM Deniau (2010)
1136 *Journal of Neuroscience Methods* **194**, 56-63.
1137 DOI: 10.1016/j.jneumeth.2009.12.014.
1138
1139 **Visual and oculomotor functions of monkey subthalamic nucleus**
1140 M Matsumura, J Kojima, TW Gardiner and O Hikosaka (1992)
1141 *Journal of Neurophysiology* **67**: 1615-1632.
1142 DOI: 10.1152/jn.1992.67.6.1615.
1143
1144 **Nociceptive neurons in rat superior colliculus: response properties, topography, and**
1145 **functional implications**
1146 JG McHaffie, CQ Kao and BE Stein (1989)
1147 *Journal of Neurophysiology* **62(2)**: 510-525.
1148 DOI: 10.1152/jn.1989.62.2.510.
1149
1150 **Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or**
1151 **both**
1152 CC McIntyre, M Savasta, L Kerkerian-Le Goff and JL Vitek (2004)
1153 *Clinical Neurophysiology* **115(6)**: 1239-48.
1154 DOI: 10.1016/j.clinph.2003.12.024
1155

- 1156 **The Rat Brain in Stereotaxic Coordinates**
1157 G Paxinos and C Watson (2005)
1158 Academic Press, Sydney
1159
- 1160 **Subthalamic neuronal firing in obsessive-compulsive disorder and Parkinson disease**
1161 B Piallat, M Polosan, V Fraix, L Goetz, O David, A Fenoy, N Torres, JL Quesada, E Seigneuret, P
1162 Pollak, P Krack, T Bougerol, AL Benabid and S Chabardès (2011)
1163 *Annals of Neurology* **69**: 793-802.
1164 DOI: 10.1002/ana.22222.
1165
- 1166 **Lateral parabrachial nucleus lesions in the rat: aversive and appetitive gustatory**
1167 **conditioning**
1168 S Reilly and R Trifunovic (2000)
1169 *Brain Research Bulletin* **52(4)**: 269-278.
1170
- 1171 **Lateral parabrachial nucleus lesions in the rat: neophobia and conditioned taste aversion**
1172 S Reilly and R Trifunovic (2001)
1173 *Brain Research Bulletin* **55(3)**: 359-366.
1174
- 1175 **Efferent connections of the parabrachial nucleus in the rat**
1176 CB Saper and AD Leowy (1980)
1177 *Brain Research* **197(2)**: 291-317.
1178
- 1179 **Branching patterns of parabrachial neurons projecting to the central extended amygdala:**
1180 **single axonal reconstructions**
1181 M Sarhan, MJ Freund-Mercier and P Veinante (2005)
1182 *Journal of Comparative Neurology* **491(4)**: 418-42.
1183 DOI: 10.1002/cne.20697.
1184
- 1185 **Neurophysiologic study of central pain in patients with Parkinson disease**
1186 P Schestatsky, H Kumru, J Valls-Solé, F Valldeoriola, MJ Marti, E Tolosa and ML Chaves (2007)
1187 *Neurology* **69(23)**: 2162-9.

1188 DOI: 10.1212/01.wnl.0000295669.12443.d3.

1189

1190 **Interactions between the basal ganglia, the pontine parabrachial region, and the**
1191 **trigeminal system in cat**

1192 P Shirvalkar, TL Veuthey, HE Dawes, EF Chang and JS Schneider (1986)

1193 *Neuroscience* **19**: 411–425.

1194

1195 **Enhanced pain-induced activity of pain processing regions in a case-control study of**
1196 **episodic migraine**

1197 TJ Schwedt, CD Chong, CC Chiang, L Baxter, BL Schlaggar and DW Dodick (2014)

1198 *Cephalalgia* **34(12)**: 947-958.

1199 DOI: 10.1177/0333102414526069.

1200

1201 **Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive**
1202 **pain in Parkinson's disease**

1203 O Sürücü, H Baumann-Vogel, M Uhl, LL Imbach and CR Baumann (2013)

1204 *Pain* **154(8)**: 1477-1479.

1205 DOI: 10.1016/j.pain.2013.03.008

1206

1207 **Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO₂**
1208 **laser evoked potentials**

1209 M Tinazzi, C Del Vesco, G Defazio, E Fincati, N Smania, G Moretto, A Fiaschi, D Le Pera and M
1210 Valeriani (2008)

1211 *Pain* **136(1-2)**: 117-24.

1212 DOI: 10.1016/j.pain.2007.06.022.

1213

1214 **Direct projections from the deep layers of the superior colliculus to the subthalamic**
1215 **nucleus in the rat**

1216 H Tokuno, M Takada, Y Ikai and N Mizuno (1994)

1217 *Brain Research* **639**: 156-160.

1218

1219 **Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives**

- 1220 M de Tommaso, L Arendt-Nielsen, R Defrin, M Kunz, G Pickering and M Valeriani (2016)
- 1221 *Behavioral Neurology* **75762922016**.
- 1222 DOI: 10.1155/2016/7576292.
- 1223
- 1224
- 1225
- 1226
- 1227
- 1228
- 1229
- 1230
- 1231

1233 Figure 1


| | Objectives | Methods | Methods illustrations |
|---|---|--|---|
| What is the link between nociception and STN ? | Are STN neurons responsive to noxious stimulation ? | Extracellular electrophysiology | <p>Can a noxious stimulus activate the STN ?</p> <p>STN single unit recording</p> |
| | Where is the nociceptive information coming from ? | Extracellular electrophysiology | <p>Can a pharmacological blockade of SC suppress STN nociceptive responses ?</p> <p>STN single unit electrode</p> <p>SC multi-unit electrode</p> <p>SC canula (muscimol - GABA agonist)</p> |
| | <p>Hypothesis 1: Superior colliculus (SC)</p> <p>Hypothesis 2: Parabrachial nucleus (PBN)</p> | | <p>Can a lesion of SC reduce the occurrence of STN nociceptive responses ?</p> <p>STN single unit electrode</p> <p>SC ibotenic acid lesion</p> |
| | | <p>Can a pharmacological blockade of PBN suppress STN nociceptive responses ?</p> <p>STN single unit electrode</p> <p>PBN multi-unit electrode</p> <p>PBN canula (muscimol - GABA agonist)</p> | |
| | | <p>Can a lesion of PBN reduce the occurrence of STN nociceptive responses ?</p> <p>STN single unit electrode</p> <p>PBN ibotenic acid lesion</p> | |
| Is STN anatomically linked to a nociceptive network ? | | Tract tracing neuro-anatomy | <p>Retrograde tracers in STN</p> <p>Anterograde tracers in PBN</p> |
| Is STN functionally relevant for nociceptive perception ? | Does a lesion of STN change the rat nociceptive response ? | Behavioral assessment | <p>STN Ibotenic acid lesion (or vehicle)</p> <p>Hot plate test</p> |
| Parkinson's disease and STN nociceptive responses | Are STN nociceptive responses abnormal in a rat model of Parkinson's disease ? | Extracellular electrophysiology | <p>Dopaminergic lesion: 6-OHDA in SNc (or vehicle)</p> <p>STN single unit recording</p> |

1234

1235 Figure 1. Summary of the objectives and methods.


1236

1237



1239

1240 **Figure 2. Histological and electrophysiological markers of recorded STN neurons** - A. Location of
 1241 recording sites within the STN. Note that the number of non-responding cells is higher in the caudal
 1242 part of STN. B. Example of triphasic (top) and biphasic (bottom) spike waveforms of STN neurons. C.
 1243 Individual recordings illustrating STN irregular (top), regular (middle) and in burst (bottom) firing
 1244 pattern. Abbreviations: F: nucleus of the fields of Forel; Gem: Gemini hypothalamic nucleus; LH:
 1245 lateral hypothalamic area; PeF: perifornical nucleus; PSTh: parasubthalamic nucleus; Subl: subincertal
 1246 nucleus; Te: terete hypothalamic nucleus; VM: ventromedial thalamic nucleus; VPL: ventral
 1247 posterolateral thalamic nucleus; VPM: ventral posteromedial thalamic nucleus; ZID: zona incerta,
 1248 dorsal part; ZIV: zona incerta, ventral part.



1249 **Figure 3**


1250

1251 **Figure 3. STN nociceptive phasic and tonic response** – A. Phasic responses. Peristimulus histograms
 1252 showing individual cases of different types of phasic noxious evoked responses in the STN. The
 1253 dashed vertical line indicates the onset time of the nociceptive footshock. The n associated with each
 1254 histogram indicated the number of cases exhibiting that class of response; total n = 98. B. Tonic
 1255 responses. Peristimulus histograms showing individual cases of decreased (left) and increased (right)
 1256 STN baseline firing rate with the nociceptive stimulation. Histograms of the group mean data (+/
 1257 sem) during the sham (dark gray) and nociceptive (light gray) stimulation showing a significant
 1258 increase or decrease of the baseline firing rate of the up ($p < 0.001$) and down group ($p < 0.001$) and
 1259 no effect of the no change group ($p = 0.1272$). Note the higher baseline firing rate of the down cells
 1260 during the sham stimulation compared to the up groups ($p < 0.05$).

1261

1262

1263 **Figure 4**



1264


1265

1266 **Figure 4: Plots of the STN lesion** - A. Schematic of the ibotenic acid STN lesions, each colour
1267 represents the plot of an individual animal. B. Coronal sections (stained with cresyl violet) of the STN

1268 following a bilateral injection of ibotenic acid. Red arrows indicate the location of the lesion and
1269 black arrows the tract of the cannula. Scale bars = 400 μ m.

1270 **Figure 5**

1271



1272

1273

1274 **Figure 5. Effect of local injection of muscimol in PBN on STN nociceptive responses.** The set of
1275 graphs presents raster displays and peri-stimulus histograms of three single cases (A, B and C) aligned
1276 on the presentation of 120 stimuli (electrical footshocks delivered at 0.5 Hz; vertical red line). Prior to
1277 the injection of muscimol, both the PBN (a, e, i) and STN (c, g, k) neurons were responsive to the
1278 footshock. Following the injection of muscimol into the PBN, local neurons became less (b, f) or
1279 unresponsive to the footshock (j) and so did the STN neurons (d, h, l). Note that PBN blockade with
1280 muscimol abolished different STN response types such as bipolar +/- (a), mono phasic short/short (g)
1281 and mono phasic short/long (k).


1282

1283

1284


1285

1286



1288

1289 **Figure 6. Effect of SC lesion on STN nociceptive responses** - A. Coronal sections (stained with cresyl
 1290 violet) of the SC following a unilateral injection of ibotenic acid (dotted line, left) and its control
 1291 contralateral side (right). Scale bars = 500 μ m. B. Schematic of a typical lesion (in gray) with ibotenic
 1292 acid in the SC. C. Plot of STN phasic nociceptive responses in the STN according to their duration
 1293 and latency in control (white) and SC lesioned (black) animals. The dotted line box highlights the
 1294 absence of long duration responses in SC lesioned rats. D. Table showing the proportion of STN
 1295 nociceptive response types in control and SC lesioned animals. Note that the proportion of STN long
 1296 lasting responses decreases in SC lesion animals.




1298

1299

1300 **Figure 7. Effect of PBN lesion on STN nociceptive responses** - A. Schematic of the ibotenic acid lesion
 1301 of the PBN. Each individual lesion is illustrated in different tone of gray. B. Coronal sections (stained
 1302 with cresyl violet) of the parabrachial nucleus following a unilateral injection of ibotenic acid (dotted
 1303 line, top) and its control contralateral side (bottom). Scale bars = 500 μ m. C. Plot of STN phasic
 1304 nociceptive responses in the STN according to their duration and latency in control (white) and
 1305 PBN lesioned (black) animals. Note that PBN lesion abolished all type of STN nociceptive responses.

1306 D. Table showing the proportion of STN nociceptive response types in control and PBN lesioned
1307 animals.

1308 **Figure 8**



1309

1310

1311 **Figure 8. Anterograde tracer in the PBN** – A. 3D renderings of parasagittal brain sections covering
1312 the PBN and STN width, illustrating the different bundles leaving the PBN following a local injection
1313 of an anterograde tracer (PHAL). B. Sagittal sections illustrating a PHAL injection site in the lateral
1314 PBN (c), associated with labeled terminals in the medial (a) and lateral (b) STN. PBN labeled terminals
1315 contain dense bouton synaptic mainly localized in STN dorsal sector (d-i). Scale bars: a-c = 200 μm, d-i
1316 = 20 μm. C. Schematic illustrating the location of terminals and synaptic in the STN following the
1317 injection of biotinylated dextran amine (BDA) in the lateral portion of the rostral PBN (insert box).



1318 Abbreviations: IC: inferior colliculus; IS: injection site; PBN: parabrachial nucleus; PPN:
1319 pedunculopontin nucleus; SC: superior colliculus; SNc: substantia nigra pars compacta; SNr:
1320 substantia nigra pars reticulata; STN: subthalamic nucleus.

1321

1322

1323

1324 **Figure 9**



1325

1326 **Figure 9. Retrograde tracer in the STN** – A. Drawing of coronal sections centered on the ipsilateral
 1327 (left) and contralateral (right) PBN to illustrate the location of the retrogradely labeled cells following
 1328 an injection of a retrograde tracer Fluorogold in the STN. B. Photomicrographs of retrogradely
 1329 labeled neurons in the PBN (a) following the injection of cholera toxin unit B (CTB) in the STN (b).
 1330 Scale bars = 200 μ m. C. Morphology of retrogradely labeled PBN neurons following an injection of
 1331 CTB into the STN. Scale bars: 20 μ m.

1332

1333


1334

1335

1336 Abbreviations: cp: cerebral peduncle; IS: injection site; IPBN: lateral parabrachial nucleus; mPBN:
 1337 medial parabrachial nucleus; scp: superior cerebral peduncle; STN: subthalamic nucleus.

1338 Note: The amplitude of the response is the maximum amplitude during the response and the
 1339 magnitude of the response is the mean number of single- multi-unit events between response onset
 1340 and offset minus the baseline mean.

| TABLE 2: NOCICEPTIVE RESPONSES IN THE SUBTHALAMIC NUCLEUS, SUPERIOR COLLICULUS AND PARABRACHIAL NUCLEUS | | | | |
|--|----------------------|----------------------|---------------------|----------------------|
| MICROINJECTION OF MUSCIMOL IN THE SUPERIOR COLLICULUS | | | | |
| | Superior colliculus | | Subthalamic nucleus | |
| | <i>Pre muscimol</i> | <i>Post muscimol</i> | <i>Pre muscimol</i> | <i>Post muscimol</i> |
| Latency | 9 ± 0.8 ms | 7.60 ± 0.68 ms | 25.33 ± 5.27 ms | 28.38 ± 7.75 ms |
| Duration | 19.62 ± 5.00 ms | 14 ± 3.03 ms | 176.13 ± 60.37 ms | 135.74 ± 50.19 ms * |
| Amplitude | 322.29 ± 58.16 Hz | 125.00 ± 26.22 Hz * | 15.61 ± 3.29 Hz | 14.4 ± 2.44 Hz |
| Magnitude | 140.20 ± 28.01 Hz | 45.01 ± 9.16 Hz * | 10.21 ± 1.99 Hz | 7.24 ± 1.41 Hz |
| Baseline FR no footshock... | 18.27 ± 2.19 Hz | - | 4.37 ± 0.8 Hz | - |
| Baseline FR footshock... | 20.79 ± 2.66 Hz | 7.69 ± 3.00 Hz * | 6.06 ± 1.48 Hz | 6.45 ± 1.38 Hz |
| MICROINJECTION OF MUSCIMOL IN THE PARABRACHIAL NUCLEUS | | | | |
| | Parabrachial nucleus | | Subthalamic nucleus | |
| | <i>Pre muscimol</i> | <i>Post muscimol</i> | <i>Pre muscimol</i> | <i>Post muscimol</i> |
| Latency | 11.55 ± 1.35 ms | 19.00 ± 2.48 ms * | 24.54 ± 3.13 ms | 18.43 ± 1.73 ms |
| Duration | 26.45.12 ± 3.85 ms | 14 ± 3.49 ms * | 98.00 ± 27.35 ms | 45.75 ± 12.04 ms * |
| Amplitude | 146.97.42 ± 23.66 Hz | 83.26 ± 17.02 Hz * | 26.98 ± 5.72 Hz | 17.18 ± 3.26 Hz * |
| Magnitude | 45.16 ± 7.45 Hz | 23.70 ± 4.57 Hz * | 10.31 ± 2 Hz | 6.65 ± 1.44 Hz * |
| Baseline FR no footshock... | 24.25 ± 1.97 Hz | - | 5.89 ± 0.49 Hz | - |
| Baseline FR footshock... | 20.55 ± 2.42 Hz | 14.15 ± 2.76 Hz | 5.50 ± 0.71 Hz | 5.39 ± 0.57 Hz |
| Mean ± SEM - * statistically different from pre muscimol measure | | | | |



1341 **Figure 10 – Supplementary results**

1342 **Figure 10** - Noxious footshock – A. Histogram showing the increase of the number of responding
 1343 cells with the increase of the footshock intensity. B. Increase of the maximum amplitude and
 1344 magnitude of phasic nociceptive evoked responses with the increase of the footshock intensity. C.
 1345 Individual example of an STN cell excited both by a mechanical noxious stimulation (pinch – left) and
 1346 a 5 mA noxious footshock (right). D. Coronal sections of the lumbar region of the spinal cord
 1347 processed for c-fos expression in an animal subjected to 1 h unilateral noxious electrical stimulation

1348 of the hindpaw (left) and in a control animal in which the electrodes were implanted into the
1349 hindpaw, but no footshock applied.